Drug · CHEMBL424
SALICYLIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SALICYLIC ACID. Drugs and targets, record CHEMBL424. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL424
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Acnisal, Bazuka, Compound v, Compound w, Cuplex verruca, Dr. scholl's callus removers, Duofilm, Edinburgh, Erytex, Freezone, Gppe paint, Jadit, Keralyt, Metanium, Necol, Noxacorn, Occlusal, Phiso-clear, Phytex, Phytocil, Posalfilin, Pyralvex, Salactol, Salatac, Thwart, Toepedo, Verrugon, Wartex
- ChEMBL
- Other names
- 2-hydroxybenzoic acid, FEMA NO. 3985, K-557, Lamivudine impurity, salicylic acid-, Lamivudine related compound salicylic acid, NSC-180, Salicylic acid rs
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases17
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acne | Approval | DailyMed | 10 | 9 | https://conductscience.org/library/drugs?q=MONDO_0011438 |
| psoriasis | Approval | DailyMed | 30 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005083 |
| common wart | Approval | DailyMed | 6 | 2 | https://conductscience.org/library/drugs?q=MONDO_0001209 |
| plantar wart | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0001795 |
| rosacea | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0006604 |
| actinic keratosis | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005173 |
| freckles | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0003963 |
| otomycosis | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0000262 |
| Pruritus | Approval | DailyMed | 23 | 0 | https://conductscience.org/library/drugs?q=HP_0000989 |
| seborrheic dermatitis | Approval | DailyMed | 22 | 0 | https://conductscience.org/library/drugs?q=MONDO_0006608 |
1 to 10 of 17Source Open Targets
See all 17 diseasesTrials33
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01706263 | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne | Phase 4 | 28 | 2018-01-08 | salicylic acid | Its name | ClinicalTrials.gov |
| NCT00616239 | Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women | Phase 4 | 20 | 2013-12-30 | salicylic acid | Its name | ClinicalTrials.gov |
| NCT00848744 | Comparison of Two Salicylic Acid Formulations | 10 | 2010-07-05 | salicylic acid | Its name | ClinicalTrials.gov | |
| NCT00944216 | Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study | Phase 4 | 1 | 2022-02-04 | salicylic acid | Its name | ClinicalTrials.gov |
| NCT01059110 | Comparison of Five Treatments in Patients With Plantar Warts | Phase 4 | 358 | salicylic acid | Its name | ClinicalTrials.gov | |
| NCT05497323 | Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA | Phase 1 | 284 | salicylic acid | Its name | ClinicalTrials.gov | |
| NCT05862441 | A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts | Phase 2/3 | 260 | salicylic acid | Its name | ClinicalTrials.gov | |
| NCT03832647 | Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne | Phase 4 | 200 | salicylic acid | Its name | ClinicalTrials.gov | |
| NCT02289768 | Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses | Phase 3 | 166 | salicylic acid | Its name | ClinicalTrials.gov | |
| NCT07329907 | Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic | Phase 2 | 126 | salicylic acid | Its name | ClinicalTrials.gov |
1 to 10 of 33
See all 33 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials38
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL424
GET https://conductscience.org/api/drugs/v1/CHEMBL424/trials?page=2